Geneva: The World Health Organization (WHO) has issued a global safety alert warning of a rare but potentially irreversible vision condition associated with popular diabetes and weight-loss drugs containing semaglutide, including Ozempic, Rybelsus, and Wegovy.
The alert, released on 27 June, highlights the risk of non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can lead to sudden, painless, and irreversible loss of vision, typically in one eye.
“There is currently no effective treatment available for NAION, and the vision loss is generally irreversible,” the WHO stated in its warning.
The European Medicines Agency (EMA) has already acted on this risk by updating the safety profiles of these drugs. Following a comprehensive safety review, the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommended that NAION be listed as a “very rare” side effect, potentially affecting up to 1 in 10,000 users.
Semaglutide, a GLP-1 receptor agonist, has seen widespread use globally for treating type 2 diabetes and obesity. However, the growing popularity of these drugs has also brought new safety concerns to light.
NAION is considered the second most common optic neuropathy after glaucoma and can present without pain, making early detection more challenging. Common symptoms include sudden vision loss and optic disc swelling.
The WHO noted that its global adverse event database, VigiBase, had received several individual case safety reports of NAION linked to semaglutide use from multiple countries. After assessing these reports during its May 2025 meeting, the WHO Advisory Committee on Safety of Medicinal Products (ACSoMP) recommended revising semaglutide’s risk management plans.
Healthcare professionals worldwide are now being urged to inform patients about this potential risk and to remain vigilant. Patients currently using semaglutide or considering it are advised to seek immediate medical help if they experience any sudden changes in vision.
The alert is part of continued pharmacovigilance efforts around GLP-1-based medications, which have transformed diabetes and obesity care but continue to face evolving scrutiny as their use expands.
